Dream Team Precision Therapy for Advanced Prostate Cancer
The “Precision Therapy for Advanced Prostate Cancer Dream Team" will establish a framework for translating research into precision prostate cancer medicine for patient care; a personalized approach to treatment.
Prostate cancer is the second most common cause of cancer deaths for men in the United States and is the second leading cause of all deaths for African American men. African American men die from prostate cancer at a rate 140% higher than all other men. There is a clear and urgent need to identify treatments and treatment approaches to reduce the prostate cancer death and suffering among all men, and especially among African Americans. Precision therapy could be a part of the solution.
Prostate cancer, like other types of cancer, is not a homogeneous disease. For example, up to 50 percent of treatment resistant metastatic prostate cancer patients have a genetic aberration called a “gene fusion” that involves two genes including ETS genes. Another 50 percent of patients may have a “deletion” or loss of an entire gene called PTEN. This diversity of prostate cancer suggests that treatment decisions will require a personalized or precision approach — matching treatment to specific characteristics of a tumor.
The Dream Team project will use genetic sequencing technology to understand cancer genomes in 500 men with treatment resistant metastatic prostate cancer. These men will then be treated with a new FDA approved drug and/or an experimental drug to understand which treatment is most effective for the different types of cancer genomes. This project is led by Dr. Arul Chinnaiyan (University of Michigan) and Dr. Charles Sawyers (Memorial Sloan Kettering Cancer Center).
The Stand Up to Cancer Foundation (SU2C) is funding the prostate cancer "Dream Team" project over a three year period. With an understanding of the prostate cancer crisis in Black America, SU2C established a goal for the project to include at least 10% African American men.
Treatments The standard of care treatment for the Dream Team project is Abiraterone (Zytiga), a treatment approved by the Federal Drug Administration (FDA) in 2011 based on clinical trials showing that it increased survival for men with advanced prostate cancer. The Dream Team project is technically a clinical trial, however, all patients that participate will receive treatment. This study does not include men receiving a placebo. Men who participate will be required to submit a tissue sample for genomic testing to determine their cancer characteristics.
Why Should African American men participate in the Dream Team Project? This is a unique opportunity to participate in a revolutionary treatment and clinical trial program with the world's leading prostate cancer doctors, researchers and scientists. Participation will benefit the patient, help determine the most effective treatment for African American men with advanced disease, and provide insight as to why the 140% higher death rate compared to other men.
How do I participate?
Men with metastatic hormone resistant prostate cancer may be eligible to participate in the Dream Team “Precision Therapy for Advanced Prostate Cancer” treatment and clinical trial program. Those men interested in this program should provide their information by clicking on the "Pre-registration button" below. It is understood that this pre-registration is not a commitment by you to participate in the program, or, a commitment by the program team that you meet the eligibility criteria. Your information will be reviewed in strict confidence by the program team. You will then be contacted directly with the appropriate follow-up instructions.